How I treat postimmunotherapy relapsed B-ALL

2.

Pulte

ED

,

Vallejo

J

,

Przepiorka

D

, et al.

FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia

.

Oncol

.

2018

;

23

(

11

):

1366

-

1371

.

3.

Maude

SL

,

Laetsch

TW

,

Buechner

J

, et al.

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

.

N Engl J Med

.

2018

;

378

(

5

):

439

-

448

.

4.

Shah

BD

,

Ghobadi

A

,

Oluwole

OO

, et al.

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

.

Lancet

.

2021

;

398

(

10299

):

491

-

502

.

5.

Gardner

RA

,

Finney

O

,

Annesley

C

, et al.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

.

Blood

.

2017

;

129

(

25

):

3322

-

3331

.

6.

Curran

KJ

,

Margossian

SP

,

Kernan

NA

, et al.

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

.

Blood

.

2019

;

134

(

26

):

2361

-

2368

.

7.

Pasquini

MC

,

Hu

ZH

,

Curran

K

, et al.

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

.

Blood Adv

.

2020

;

4

(

21

):

5414

-

5424

.

8.

Shah

NN

,

Lee

DW

,

Yates

B

, et al.

Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

.

J Clin Oncol

.

2021

;

39

(

15

):

1650

-

1659

.

9.

Kadauke

S

,

Myers

RM

,

Li

Y

, et al.

Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial

.

J Clin Oncol

.

2021

;

39

(

8

):

920

-

930

.

10.

Laetsch

TW

,

Maude

SL

,

Rives

S

, et al.

Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA Trial

.

J Clin Oncol

.

2023

;

41

(

9

):

1664

-

1669

.

11.

Lamble

A

,

Myers

RM

,

Taraseviciute

A

, et al.

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

.

Blood Adv

.

2023

;

7

(

4

):

575

-

585

.

12.

Majzner

RG

,

Mackall

CL

.

Tumor antigen escape from CAR T-cell therapy

.

Cancer Discov

.

2018

;

8

(

10

):

1219

-

1226

.

13.

Schultz

LM

,

Eaton

A

,

Baggott

C

, et al.

Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia

.

J Clin Oncol

.

2023

;

41

(

2

):

354

-

363

.

14.

Locatelli

F

,

Shah

B

,

Thomas

T

, et al.

Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review

.

Leuk Lymphoma

.

2023

;

64

(

10

):

1615

-

1633

.

15.

Short

NJ

,

Macaron

W

,

Konopleva

M

, et al.

Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab

.

Am J Hematol

.

2022

;

97

(

6

):

E201

-

E204

.

16.

Pulsipher

MA

,

Han

X

,

Maude

SL

, et al.

Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia

.

Blood Cancer Discov

.

2022

;

3

(

1

):

66

-

81

.

17.

Liang

EC

,

Dekker

SE

,

Sabile

JMG

, et al.

Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation

.

Blood Adv

.

2023

;

7

(

14

):

3395

-

3402

.

18.

Muffly

L

,

Liang

EC

,

Dolan

JG

,

Pulsipher

MA

.

How I use next generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL

.

Blood

.

2024

;

144

(

3

):

253

-

261

.

19.

Heslop

HE

,

Stadtmauer

EA

,

Levine

JE

, et al.

Blood and marrow transplant clinical trials network state of the science symposium 2021: looking forward as the network celebrates its 20th year

.

Transplant Cell Ther

.

2021

;

27

(

11

):

885

-

907

.

20.

Lamble

AJ

,

Moskop

A

,

Pulsipher

MA

, et al.

INSPIRED Symposium Part 2: prevention and management of relapse following chimeric antigen receptor T cell therapy for B cell acute lymphoblastic leukemia

.

Transplant Cell Ther

.

2023

;

29

(

11

):

674

-

684

.

21.

Frigault

MJ

,

Dietrich

J

,

Martinez-Lage

M

, et al.

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma

.

Blood

.

2019

;

134

(

11

):

860

-

866

.

22.

Jacoby

E

,

Ghorashian

S

,

Vormoor

B

, et al.

CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study

.

Leukemia

.

2022

;

36

(

6

):

1525

-

1532

.

23.

Karschnia

P

,

Arrillaga-Romany

IC

,

Eichler

A

, et al.

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells

.

Neuro Oncol

.

2023

;

25

(

12

):

2239

-

2249

.

24.

Turtle

CJ

,

Hanafi

LA

,

Berger

C

, et al.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

.

J Clin Invest

.

2016

;

126

(

6

):

2123

-

2138

.

25.

Myers

RM

,

Devine

KJ

,

Li

Y

, et al.

Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia

.

Blood Adv

.

2024

;

8

(

9

):

2182

-

2192

.

26.

Gauthier

J

,

Bezerra

ED

,

Hirayama

AV

, et al.

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

.

Blood

.

2021

;

137

(

3

):

323

-

335

.

27.

Myers

RM

,

Li

Y

,

Barz Leahy

A

, et al.

Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia

.

J Clin Oncol

.

2021

;

39

(

27

):

3044

-

3055

.

28.

Gore

L

,

Locatelli

F

,

Zugmaier

G

, et al.

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

.

Blood Cancer J

.

2018

;

8

(

9

):

80

.

29.

Locatelli

F

,

Zugmaier

G

,

Rizzari

C

, et al.

Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial

.

JAMA

.

2021

;

325

(

9

):

843

-

854

.

30.

Duell

J

,

Dittrich

M

,

Bedke

T

, et al.

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

.

Leukemia

.

2017

;

31

(

10

):

2181

-

2190

.

31.

Feucht

J

,

Kayser

S

,

Gorodezki

D

, et al.

T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts

.

Oncotarget

.

2016

;

7

(

47

):

76902

-

76919

.

32.

Topp

MS

,

Stelljes

M

,

Zugmaier

G

, et al.

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

.

Leukemia

.

2018

;

32

(

2

):

562

-

565

.

33.

Myers

RM

,

Taraseviciute

A

,

Steinberg

SM

, et al.

Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL

.

J Clin Oncol

.

2022

;

40

(

9

):

932

-

944

.

34.

Summers

C

,

Wu

QV

,

Annesley

C

, et al.

Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage

.

Transplant Cell Ther

.

2022

;

28

(

1

):

21

-

29

.

35.

Gabelli

M

,

Oporto-Espuelas

M

,

Burridge

S

, et al.

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy

.

Blood Adv

.

2024

;

8

(

8

):

1959

-

1963

.

36.

Sotillo

E

,

Barrett

DM

,

Black

KL

, et al.

Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy

.

Cancer Discov

.

2015

;

5

(

12

):

1282

-

1295

.

37.

Agrawal

V

,

Salhotra

A

,

Song

J

, et al.

The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse

.

Am J Hematol

.

2023

;

98

(

2

):

E38

-

E40

.

38.

Aminov

S

,

Giricz

O

,

Melnekoff

DT

, et al.

Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

.

J Clin Invest

.

2024

;

134

(

8

):

e175199

.

39.

Wang

L

,

Zhang

Y

,

Anderson

E

,

Lamble

A

,

Orentas

RJ

.

Bryostatin activates CAR T-cell antigen-non-specific killing (CTAK), and CAR-T NK-like killing for pre-B ALL, while blocking cytolysis of a Burkitt lymphoma cell line

.

Front Immunol

.

2022

;

13

:

825364

.

40.

Holland

EM

,

Molina

JC

,

Dede

K

, et al.

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation

.

J Immunother Cancer

.

2022

;

10

(

5

):

e004483

.

41.

Rubinstein

JD

,

O'Brien

MM

.

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations

.

Front Immunol

.

2023

;

14

:

1237738

.

42.

Kantarjian

HM

,

Stock

W

,

Cassaday

RD

, et al.

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE Trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22

.

Clin Cancer Res

.

2021

;

27

(

10

):

2742

-

2754

.

43.

Kouhi

A

,

Pachipulusu

V

,

Kapenstein

T

,

Hu

P

,

Epstein

AL

,

Khawli

LA

.

Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives

.

Int J Mol Sci

.

2021

;

22

(

12

):

6442

.

44.

DeAngelo

DJ

,

Advani

AS

,

Marks

DI

, et al.

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

.

Blood Cancer J

.

2020

;

10

(

8

):

81

.

45.

Alban

J

,

DuVall

A

,

Gurbuxani

S

,

Stock

W

,

Patel

AA

.

Outcomes after retreatment with inotuzumab ozogamicin for relapsed/refractory philadelphia chromosome-negative B-cell acute lymphoblastic leukemia

.

JCO Precis Oncol

.

2022

;

6

:

e2200353

.

46.

Bhojwani

D

,

Sposto

R

,

Shah

NN

, et al.

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

.

Leukemia

.

2019

;

33

(

4

):

884

-

892

.

47.

Kantarjian

HM

,

DeAngelo

DJ

,

Stelljes

M

, et al.

Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia

.

N Engl J Med

.

2016

;

375

(

8

):

740

-

753

.

48.

Kantarjian

HM

,

DeAngelo

DJ

,

Advani

AS

, et al.

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

.

Lancet Haematol

.

2017

;

4

(

8

):

e387

-

e398

.

49.

Mohty

M

,

Malard

F

,

Abecassis

M

, et al.

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

.

Bone Marrow Transplant

.

2015

;

50

(

6

):

781

-

789

.

50.

Kebriaei

P

,

Cutler

C

,

de Lima

M

, et al.

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

.

Bone Marrow Transplant

.

2018

;

53

(

4

):

449

-

456

.

51.

Sabatino

D

,

Henneman

A

,

Ahmad

S

,

Jou

E

,

Goldberg

B

.

Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin

.

J Oncol Pharm Pract

.

2023

;

29

(

4

):

840

-

845

.

52.

Giglio

F

,

Xue

E

,

Greco

R

, et al.

Defibrotide prophylaxis of sinusoidal obstruction syndrome in adults treated with inotuzumab ozogamicin prior to hematopoietic stem cell transplantation

.

Front Oncol

.

2022

;

12

:

933317

.

53.

Grupp

SA

,

Corbacioglu

S

,

Kang

HJ

, et al.

Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial

.

Lancet Haematol

.

2023

;

10

(

5

):

e333

-

e345

.

54.

Shah

NN

,

Highfill

SL

,

Shalabi

H

, et al.

CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-Cell Trial

.

J Clin Oncol

.

2020

;

38

(

17

):

1938

-

1950

.

55.

Hines

MR

,

Knight

TE

,

McNerney

KO

, et al.

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome

.

Transplant Cell Ther

.

2023

;

29

(

7

):

438.e1

-

438.e16

.

56.

O'Brien

MM

,

Ji

L

,

Shah

NN

, et al.

Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621

.

J Clin Oncol

.

2022

;

40

(

9

):

956

-

967

.

57.

Shah

NN

,

Stevenson

MS

,

Yuan

CM

, et al.

Characterization of CD22 expression in acute lymphoblastic leukemia

.

Pediatr Blood Cancer

.

2015

;

62

(

6

):

964

-

969

.

58.

O'Brien

MM

,

McNeer

JL

,

Rheingold

SR

, et al.

A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: second safety phase results from Children’s Oncology Group AALL1732

.

J Clin Oncol

.

2023

;

41

(

16 suppl

):

10016

.

59.

Spiegel

JY

,

Patel

S

,

Muffly

L

, et al.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

.

Nat Med

.

2021

;

27

(

8

):

1419

-

1431

.

60.

Cordoba

S

,

Onuoha

S

,

Thomas

S

, et al.

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

.

Nat Med

.

2021

;

27

(

10

):

1797

-

1805

.

61.

Shalabi

H

,

Qin

H

,

Su

A

, et al.

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

.

Blood

.

2022

;

140

(

5

):

451

-

463

.

62.

Wood

BL

.

Acute myeloid leukemia minimal residual disease detection: the difference from normal approach

.

Curr Protoc Cytom

.

2020

;

93

(

1

):

e73

.

63.

Zhou

T

,

Curry

CV

,

Khanlari

M

, et al.

Genetics and pathologic landscape of lineage switch of acute leukemia during therapy

.

Blood Cancer J

.

2024

;

14

(

1

):

19

.

64.

Rayes

A

,

McMasters

RL

,

O'Brien

MM

.

Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy

.

Pediatr Blood Cancer

.

2016

;

63

(

6

):

1113

-

1115

.

65.

Oberley

MJ

,

Gaynon

PS

,

Bhojwani

D

, et al.

Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia

.

Pediatr Blood Cancer

.

2018

;

65

(

9

):

e27265

.

66.

Wolfl

M

,

Rasche

M

,

Eyrich

M

,

Schmid

R

,

Reinhardt

D

,

Schlegel

PG

.

Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL

.

Blood Adv

.

2018

;

2

(

12

):

1382

-

1385

.

67.

Mejstrikova

E

,

Hrusak

O

,

Borowitz

MJ

, et al.

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

.

Blood Cancer J

.

2017

;

7

(

12

):

659

.

68.

Du

J

,

Chisholm

KM

,

Tsuchiya

K

, et al.

Lineage switch in an infant B-lymphoblastic leukemia with t(1;11)(p32;q23); KMT2A/EPS15, following blinatumomab therapy

.

Pediatr Dev Pathol

.

2021

;

24

(

4

):

378

-

382

.

69.

Aldoss

I

,

Song

JY

.

Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab

.

Blood

.

2018

;

131

(

22

):

2507

.

70.

Balducci

E

,

Nivaggioni

V

,

Boudjarane

J

, et al.

Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy

.

Ann Hematol

.

2017

;

96

(

9

):

1579

-

1581

.

71.

Fournier

E

,

Inchiappa

L

,

Delattre

C

, et al.

Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature

.

Leuk Lymphoma

.

2019

;

60

(

7

):

1827

-

1830

.

72.

Gardner

R

,

Wu

D

,

Cherian

S

, et al.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

.

Blood

.

2016

;

127

(

20

):

2406

-

2410

.

73.

Haddox

CL

,

Mangaonkar

AA

,

Chen

D

, et al.

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis

.

Blood Cancer J

.

2017

;

7

(

9

):

e607

.

74.

He

RR

,

Nayer

Z

,

Hogan

M

, et al.

Immunotherapy- (blinatumomab-) related lineage switch of KMT2A/AFF1 rearranged B-lymphoblastic leukemia into acute myeloid leukemia/myeloid sarcoma and subsequently into B/myeloid mixed phenotype acute leukemia

.

Case Rep Hematol

.

2019

;

2019

:

7394619

.

75.

Zoghbi

A

,

Zur Stadt

U

,

Winkler

B

,

Muller

I

,

Escherich

G

.

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement

.

Pediatr Blood Cancer

.

2017

;

64

(

11

).

76.

Silbert

SK

,

Harrison

C

,

Biery

DN

, et al.

Project evolve, evaluation of lineage switch (LS), an international initiative: preliminary results reveal dismal outcomes in patients with LS [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4202

.

77.

Lee

BM

,

Summers

C

,

Chisholm

KM

, et al.

Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy

.

Blood Adv

.

2023

;

7

(

12

):

2825

-

2830

.

78.

Cooper

TM

,

Absalon

MJ

,

Alonzo

TA

, et al.

Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the Children's Oncology Group

.

J Clin Oncol

.

2020

;

38

(

19

):

2170

-

2177

.

79.

Pollard

JA

,

Guest

E

,

Alonzo

TA

, et al.

Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children's Oncology Group Trial AAML0531

.

J Clin Oncol

.

2021

;

39

(

28

):

3149

-

3160

.

80.

Penel-Page

M

,

Plesa

A

,

Girard

S

,

Marceau-Renaut

A

,

Renard

C

,

Bertrand

Y

.

Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: a single-center experience

.

Pediatr Blood Cancer

.

2020

;

67

(

6

):

e28305

.

81.

Dalle

JH

,

Giralt

SA

.

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment

.

Biol Blood Marrow Transplant

.

2016

;

22

(

3

):

400

-

409

.

82.

Ovilla-Martinez

R

,

Weber Sanchez

LA

,

Cota-Rangel

X

,

Baez-Islas

PE

.

Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia

.

BMJ Case Rep

.

2021

;

14

(

11

):

e243745

.

83.

Brethon

B

,

Lainey

E

,

Caye-Eude

A

, et al.

Case report: targeting 2 antigens as a promising strategy in mixed phenotype acute leukemia: combination of blinatumomab with gemtuzumab ozogamicin in an infant with a KMT2A-rearranged leukemia

.

Front Oncol

.

2021

;

11

:

637951

.

84.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

85.

DiNardo

CD

,

Pratz

K

,

Pullarkat

V

, et al.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

.

Blood

.

2019

;

133

(

1

):

7

-

17

.

86.

Karol

SE

,

Alexander

TB

,

Budhraja

A

, et al.

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study

.

Lancet Oncol

.

2020

;

21

(

4

):

551

-

560

.

87.

Borowitz

MJ

,

Wood

BL

,

Keeney

M

,

Hedley

BD

.

Measurable residual disease detection in B-acute lymphoblastic leukemia: the Children's Oncology Group (COG) Method

.

Curr Protoc

.

2022

;

2

(

3

):

e383

.

88.

Borowitz

MJ

,

Devidas

M

,

Hunger

SP

, et al.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

.

Blood

.

2008

;

111

(

12

):

5477

-

5485

.

89.

Theunissen

PMJ

,

Sedek

L

,

De Haas

V

, et al.

Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection

.

Br J Haematol

.

2017

;

178

(

2

):

257

-

266

.

90.

Theunissen

P

,

Mejstrikova

E

,

Sedek

L

, et al.

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

.

Blood

.

2017

;

129

(

3

):

347

-

357

.

91.

Wang

W

,

Gao

L

,

Li

Y

, et al.

The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia

.

Leuk Lymphoma

.

2016

;

57

(

5

):

1174

-

1181

.

92.

Muzzafar

T

,

Medeiros

LJ

,

Wang

SA

,

Brahmandam

A

,

Thomas

DA

,

Jorgensen

JL

.

Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry

.

Am J Clin Pathol

.

2009

;

132

(

5

):

692

-

698

.

93.

Tsitsikov

E

,

Harris

MH

,

Silverman

LB

,

Sallan

SE

,

Weinberg

OK

.

Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia

.

Int J Lab Hematol

.

2018

;

40

(

3

):

343

-

351

.

94.

Boris

E

,

Theron

A

,

Montagnon

V

, et al.

Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia

.

Cytometry B Clin Cytom

.

2024

;

106

(

1

):

45

-

57

.

95.

Chatterjee

G

,

Dhende

P

,

Raj

S

, et al.

15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges

.

Eur J Haematol

.

2024

;

112

(

1

):

122

-

136

.

96.

Sedek

L

,

Theunissen

P

,

Sobral da Costa

E

, et al.

Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia

.

J Immunol Methods

.

2019

;

475

:

112429

.

97.

Cherian

S

,

Miller

V

,

McCullouch

V

,

Dougherty

K

,

Fromm

JR

,

Wood

BL

.

A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy

.

Cytometry B Clin Cytom

.

2018

;

94

(

1

):

112

-

120

.

98.

Cherian

S

,

Stetler-Stevenson

M

.

Flow cytometric monitoring for residual disease in B lymphoblastic leukemia post T cell engaging targeted therapies

.

Curr Protoc Cytom

.

2018

;

86

(

1

):

e44

.

99.

Li

W

,

Morgan

R

,

Nieder

R

,

Truong

S

,

Habeebu

SSM

,

Ahmed

AA

.

Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry

.

Cytometry B Clin Cytom

.

2021

;

100

(

5

):

590

-

601

.

100.

Pulsipher

MA

,

Carlson

C

,

Langholz

B

, et al.

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

.

Blood

.

2015

;

125

(

22

):

3501

-

3508

.

101.

Wang

X

,

Dong

Z

,

Awuah

D

, et al.

CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia

.

Leukemia

.

2022

;

36

(

4

):

1015

-

1024

.